We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
IMFINZI AstraZeneca Pty Ltd
Product name
IMFINZI
Sponsor
Accepted date
Aug-2024
Active ingredients
durvalumab
Proposed indication
For the treatment of patients with limited-stage small cell lung cancer.
Application type
C (new indication)
Publication date
Aug-2024
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.